| An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment (NCT01770652) | ApoPharma | 2013-01-01 |
| A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function (NCT01761773) | Exelixis | 2012-12-01 |
| Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment (NCT01763190) | Bristol-Myers Squibb | 2012-11-01 |
| Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal) (NCT01575925) | Celgene | 2012-06-01 |
| A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers (NCT01578928) | Novartis Pharmaceuticals | 2012-05-01 |
| Pharmacokinetics of LCQ908 in Patients With Renal Impairment (NCT01558323) | Novartis Pharmaceuticals | 2012-05-01 |
| Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment (NCT01555008) | Lexicon Pharmaceuticals | 2012-03-01 |
| Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function (NCT01526746) | Vanda Pharmaceuticals | 2012-02-01 |
| Pharmacokinetics in Subjects With Renal Impairment (NCT01504165) | Merck KGaA, Darmstadt, Germany | 2012-01-01 |
| Evaluation of Colchicine and Nonsteroidal Anti-inflammatory Drug Combination Therapy and Renal Function in Gout Patients (NCT05006001) | En Chu Kong Hospital | 2012-01-01 |
| A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function (NCT01419041) | Pfizer | 2011-11-01 |
| NAG-excretion During Cardiopulmonary Bypass (NCT02410642) | Sahlgrenska University Hospital | 2011-11-01 |
| Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis (NCT01464931) | Amgen | 2011-11-01 |
| A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects (NCT02199379) | Eisai Inc. | 2011-11-01 |
| Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB) (NCT02405195) | Sahlgrenska University Hospital | 2011-10-01 |
| A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function (NCT01331941) | Amgen | 2011-09-19 |
| A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment (NCT01443429) | Toray Industries, Inc | 2011-08-01 |
| Pharmacokinetics of BF2.649 in Renal Impairment (NCT01619033) | Bioprojet | 2011-07-01 |
| CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation (NCT01023542) | University of Regensburg | 2011-06-01 |
| Safinamide Renal Impairment Trial (NCT01374113) | Newron Pharmaceuticals SPA | 2011-06-01 |
| Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function (NCT01372826) | AstraZeneca | 2011-06-01 |
| A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function (NCT01359579) | Anthera Pharmaceuticals | 2011-06-01 |
| A Phase I Clinical Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36 (NCT01372124) | TME Pharma AG | 2011-06-01 |
| Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects (NCT01459250) | Novartis Pharmaceuticals | 2011-03-01 |
| A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment (NCT01319266) | Cephalon | 2011-03-01 |
| Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment (NCT02244762) | Zogenix, Inc. | 2011-02-01 |
| A Study of Fostamatinib in Subjects With Impaired Kidney Function (NCT01245790) | AstraZeneca | 2010-11-01 |
| Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment (NCT01239459) | Sanofi | 2010-11-01 |
| To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function (NCT01240967) | AstraZeneca | 2010-11-01 |
| Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment (NCT01613690) | Novartis Pharmaceuticals | 2010-06-01 |
| A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Renal Impairment Patients and Healthy Volunteers (NCT01148368) | Boryung Pharmaceutical Co., Ltd | 2010-06-01 |
| The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847 (NCT01141179) | LEO Pharma | 2010-05-01 |
| Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment (NCT01104662) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2010-04-19 |
| Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment (NCT01120314) | Sanofi | 2010-04-01 |
| Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment (NCT01082640) | Takeda | 2010-04-01 |
| A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment (NCT00785772) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2010-03-01 |
| ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis (NCT01083888) | Astellas Pharma Inc | 2010-02-15 |
| Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study (NCT00706771) | Austin Health | 2010-02-01 |
| Pharmacokinetics of 10 mg Teduglutide in Subjects With Renal Impairment Compared to Healthy Subjects With Normal Renal Function (NCT01028768) | Nycomed | 2009-10-01 |
| Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment (NCT00984113) | Portola Pharmaceuticals | 2009-09-01 |
| Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function (NCT00879645) | Mallinckrodt | 2009-08-01 |
| Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment (NCT00958269) | Phenomix | 2009-08-01 |
| A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment (NCT00999336) | Portola Pharmaceuticals | 2009-07-31 |
| Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis (NCT02596945) | Hoffmann-La Roche | 2009-07-31 |
| Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes (NCT00948116) | Barts & The London NHS Trust | 2009-06-24 |
| Effect of Renal Impairment on the Pharmacokinetics of NN9535 (NCT00833716) | Novo Nordisk A/S | 2009-02-02 |
| Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography (NCT00793182) | Guerbet | 2009-01-01 |
| Safety of Gadovist in Renally Impaired Patients (NCT00828737) | Bayer | 2008-12-01 |
| Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients (NCT00818571) | Novartis Pharmaceuticals | 2008-12-01 |
| A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment (NCT00768404) | VIVUS LLC | 2008-10-01 |
| Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females (NCT00787618) | Repros Therapeutics Inc. | 2008-10-01 |
| Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment (NCT00828438) | Eisai Inc. | 2008-10-01 |
| A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment (NCT00750620) | Astellas Pharma Inc | 2008-09-01 |
| The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases (NCT00842868) | Massachusetts General Hospital | 2008-09-01 |
| Safety Study of AZD5672 in Renally Impaired Subjects (NCT00715702) | AstraZeneca | 2008-07-01 |
| Fluid Investigation Colloid vs Crystalloid Reg. Renal Hemodynamics and Function (NCT01729364) | Sahlgrenska University Hospital | 2008-04-01 |
| Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment (NCT00785551) | Mutual Pharmaceutical Company, Inc. | 2007-11-01 |
| Fanconi Syndrome Due to ARVs in HIV-Infected Persons (NCT00499187) | Gilead Sciences | 2007-09-01 |
| Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers (NCT00733265) | AstraZeneca | 2007-02-01 |
| Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography (NCT00335101) | GE Healthcare | 2006-06-01 |
| Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study (NCT00852800) | Hospital de Clinicas de Porto Alegre | 2006-03-01 |
| Evaluating Patients With Varying Degrees of Renal Function (NCT00398307) | Taiho Oncology, Inc. | 2006-02-01 |
| Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment (NCT00445302) | Genzyme, a Sanofi Company | 2006-01-01 |
| Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients (NCT00652782) | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2004-12-01 |
| Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal Impairment Compared to Healthy Subjects (NCT01796938) | UCB BIOSCIENCES GmbH | 2004-06-01 |
| A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function (NCT00791401) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-04-01 |
| Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function (NCT01367509) | Bausch Health Americas, Inc. | 2004-03-01 |
| Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function (NCT01740362) | Pfizer | 2003-10-01 |
| Olmesartan Medoxomil in Hypertension and Renal Impairment (NCT00151827) | Sankyo Pharma Gmbh | 2003-08-01 |
| Blood Products in Cardiac Surgery (NCT02068755) | University of Turku | 2002-01-01 |